Novo Nordisk: positive results on diabetes pen Xultophy.
(CercleFinance.com) - A phase 3b clinical trial has showed that Novo Nordisk's Xultophy is a better option to manage diabetes compared to multiple daily injections of insulin.
In the trial including 506 adults living with type-2 diabetes assessing their physical health, mental health and a number of diabetes-specific factors, Xultophy was reported by participants as "a better option" than basal-bolus insulin therapy.
In addition, more people preferred to stay on Xultophy, a once-daily single injection in one pen, rather on basal-bolus therapy (84.5% versus 68.1%), the results showed.
Novo Nordisk has presented these results today at the International Diabetes Federation Congress in Abu Dhabi.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In the trial including 506 adults living with type-2 diabetes assessing their physical health, mental health and a number of diabetes-specific factors, Xultophy was reported by participants as "a better option" than basal-bolus insulin therapy.
In addition, more people preferred to stay on Xultophy, a once-daily single injection in one pen, rather on basal-bolus therapy (84.5% versus 68.1%), the results showed.
Novo Nordisk has presented these results today at the International Diabetes Federation Congress in Abu Dhabi.
Copyright (c) 2017 CercleFinance.com. All rights reserved.